1. Гусев Е.И, Бойко А., Столяров И. Рассеянный Склероз. Москва: РеалТайм; 2009.

2. Ramagopalan S.V., et al., Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol, 2010. 9(7): p. 727 - 39.

3. Loma I. and R. Heyman, Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol, 2011. 9(3): p. 409 - 16.

4. Thompson AJ, Baneke P. Multiple Sclerosis International Federation (MSIF) Design and Editorial Support by Summers Editorial & Design Graphics by Nutmeg Productions Printed by Modern Colour Solutions.; 2013. www.msif.org. Accessed April 13, 2020.

5. Thompson A.J., et al., Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol, 2018. 17(2): p. 162 - 173.

6. Gusev E, Boiko A, Bikova O, et al. The natural history of early onset multiple sclerosis: Comparison of data from Moscow and Vancouver. In: Clinical Neurology and Neurosurgery. Vol 104. Clin Neurol Neurosurg; 2002: 203 - 207. doi: 10.1016/S0303-8467(02)00039-2

7. Simone I.L., et al., Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology, 2002. 59(12): p. 1922 - 8.

8. Jeong A, Oleske DM, Holman J. Epidemiology of Pediatric-Onset Multiple Sclerosis: A Systematic Review of the Literature. J Child Neurol. 2019 Oct; 34(12): 705 - 712. doi: 10.1177/0883073819845827.

9. Lublin F.D., et al., Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology, 2014. 83(3): p. 278 - 86.

10. Lublin F.D., et al., How patients with multiple sclerosis acquire disability. Brain, 2022. 145(9): p. 3147 - 3161.

11. Kaunzner U.W., et al., A study of patients with aggressive multiple sclerosis at disease onset. Neuropsychiatr Dis Treat, 2016. 12: p. 1907 - 12.

12. CHMP. Committee for Medicinal Products for Human Use (CHMP) Assessment Report.; 2014. www.ema.europa.eu. Accessed April 13, 2020.

13. Cree B.A., et al., Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. Mult Scler, 2021. 27(14): p. 2219 - 2231.

14. van der Vuurst de Vries, R.M., et al., Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. JAMA Neurol, 2018. 75(11): p. 1392 - 1398.

15. Lee D.H., et al., Diagnostic value of the 2017 McDonald criteria in patients with a first demyelinating event suggestive of relapsing-remitting multiple sclerosis. Eur J Neurol, 2019. 26(3): p. 540 - 545.

16. Miclea A., et al., Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study. Ther Adv Neurol Disord, 2019. 12: p. 1756286419835652.

17. Wong Y.Y.M., et al., Real-world validation of the 2017 McDonald criteria for pediatric MS. Neurol Neuroimmunol Neuroinflamm, 2019. 6(2): p. e528.

18. Fadda G., et al., MRI and laboratory features and the performance of international criteria in the diagnosis of multiple sclerosis in children and adolescents: a prospective cohort study. Lancet Child Adolesc Health, 2018. 2(3): p. 191 - 204.

19. Krupp L.B., et al., International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler, 2013. 19(10): p. 1261 - 7.

20. Solomon A.J., et al., The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study. Neurology, 2016. 87(13): p. 1393 - 9.

21. Yamout B.I., et al., Alternative diagnoses in patients referred to specialized centers for suspected MS. Mult Scler Relat Disord, 2017. 18: p. 85 - 89.

22. Solomon A.J., E.P. Klein, and D. Bourdette, "Undiagnosing" multiple sclerosis: the challenge of misdiagnosis in MS. Neurology, 2012. 78(24): p. 1986 - 91.

23. Ghezzi A., et al., Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol, 1999. 246(9): p. 770 - 5.

24. Meyer-Moock S., et al., Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol, 2014. 14: p. 58.

25. Bin Sawad A., et al., Evaluation of the Expanded Disability Status Scale and the Multiple Sclerosis Functional Composite as clinical endpoints in multiple sclerosis clinical trials: quantitative meta-analyses. Curr Med Res Opin, 2016. 32(12): p. 1969 - 1974.

26. Степанова А.Д. Валидация расширенной шкалы статуса инвалидизации (РШСИ) на русском языке для пациентов с рассеянным склерозом в Российской Федерации/А.Д. Степанова, Е.П. Евдошенко, М.В. Шумилина, Д.С. Коробко, М.А. Барабанова, М.В. Аброськина, А.Ф. Василенко, Ю.Н. Юрченко, М.В. Давыдовская//Медицинские технологии. Оценка и выбор^ 2023. Вып. 45(1): 38 - 46. https://doi.org/10.17116/medtech20234501138

27. Perry M., et al., Multiple sclerosis: summary of NICE guidance. BMJ, 2014. 349: p. g5701.

28. Epstein D.J., J. Dunn, and S. Deresinski, Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. Open Forum Infect Dis, 2018. 5(8): p. ofy174.

29. Toledano M., B.G. Weinshenker, and A.J. Solomon, A Clinical Approach to the Differential Diagnosis of Multiple Sclerosis. Curr Neurol Neurosci Rep, 2015. 15(8): p. 57.

30. Keat Wei L., et al., Association of Medicina (Kaunas), 2019. 55(7).

31. Senol M.G., et al., Reversible myelopathy with vitamin B12 deficiency. Singapore Med J, 2008. 49(11): p. e330 - 2.

32. Hammarin A.L., et al., Analysis of PCR as a tool for detection of JC virus DNA in cerebrospinal fluid for diagnosis of progressive multifocal leukoencephalopathy. J Clin Microbiol, 1996. 34(12): p. 2929 - 32.

33. Giovannoni G., et al., Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. Pract Neurol, 2016. 16(5): p. 389 - 93.

34. Ruiz-Gaviria R., et al., Specificity and sensitivity of aquaporin 4 antibody detection tests in patients with neuromyelitis optica: A meta-analysis. Mult Scler Relat Disord, 2015. 4(4): p. 345 - 9.

35. Slater C.A., R.B. Davis, and R.H. Shmerling, Antinuclear antibody testing. A study of clinical utility. Arch Intern Med, 1996. 156(13): p. 1421 - 5.

36. Leuchten N., et al., Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. Arthritis Care Res (Hoboken), 2018. 70(3): p. 428 - 438.

37. Haga HJ, Hulten B, Bolstad AI, Ulvestad E, Jonsson R. Reliability and sensitivity of diagnostic tests for primary Sjogren's syndrome. J Rheumatol. 1999; 26(3): 604 - 608.

38. Dobson R., et al., Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry, 2013. 84(8): p. 909 - 14.

39. Villar L.M., et al., CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol, 2009. 211(1-2): p. 101 - 4.

40. Skov A.G., T. Skov, and J.L. Frederiksen, Oligoclonal bands predict multiple sclerosis after optic neuritis: a literature survey. Mult Scler, 2011. 17(4): p. 404 - 10.

41. Bourahoui A., et al., CSF isoelectrofocusing in a large cohort of MS and other neurological diseases. Eur J Neurol, 2004. 11(8): p. 525 - 9.

42. Arrambide G., et al., The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain, 2018. 141(4): p. 1075 - 1084.

43. Kuhle J., et al., Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler, 2015. 21(8): p. 1013 - 24.

44. Carmosino M.J., et al., Initial evaluations for multiple sclerosis in a university multiple sclerosis center: outcomes and role of magnetic resonance imaging in referral. Arch Neurol, 2005. 62(4): p. 585 - 90.

45. Zhang W.Y. and Y.L. Hou, Prognostic value of magnetic resonance imaging in patients with clinically isolated syndrome conversion to multiple sclerosis: a meta-analysis. Neurol India, 2013. 61(3): p. 231 - 8.

46. Брюхов В. Стандартизация МРТ-исследований при рассеянном склерозе/Брюхов В, Кротенкова И, Морозова С, Кротенкова М//Журнал неврологии и психиатрии им Корсакова. - 2016. - 10(2). - 27 - 34.

47. Sombekke M.H., et al., Spinal cord lesions in patients with clinically isolated syndrome: a powerful tool in diagnosis and prognosis. Neurology, 2013. 80(1): p. 69 - 75.

48. Traboulsee A., et al., Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis. AJNR Am J Neuroradiol, 2016. 37(3): p. 394 - 401.

49. Dalton C.M., et al., New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol, 2003. 53(5): p. 673 - 6.

50. Pestalozza I.F., et al., Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome. Mult Scler, 2005. 11(4): p. 390 - 4.

51. Wattjes M.P., et al., 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol, 2021. 20(8): p. 653 - 670.

52. Alessandrino F., et al., Do MRI Structured Reports for Multiple Sclerosis Contain Adequate Information for Clinical Decision Making? AJR Am J Roentgenol, 2018. 210(1): p. 24 - 29.

53. Arevalo O., et al., Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines. J Comput Assist Tomogr, 2019. 43(1): p. 1 - 12.

54. Kupersmith M.J., et al., Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain, 2002. 125 (Pt 4): p. 812 - 22.

55. Frederiksen J.L. and J. Petrera, Serial visual evoked potentials in 90 untreated patients with acute optic neuritis. Surv Ophthalmol, 1999. 44 Suppl 1: p. S54 - 62.

56. Petzold A., et al., Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol, 2010. 9(9): p. 921 - 32.

57. Martinez-Lapiscina E.H., et al., Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol, 2016. 15(6): p. 574 - 84.

58. Britze J., G. Pihl-Jensen, and J.L. Frederiksen, Retinal ganglion cell analysis in multiple sclerosis and optic neuritis: a systematic review and meta-analysis. J Neurol, 2017. 264(9): p. 1837 - 1853.

59. (UK) NCGC. Multiple Sclerosis. National Institute for Health and Care Excellence (UK); 2014. http://www.ncbi.nlm.nih.gov/pubmed/25340249. Accessed April 13, 2020.

60. Miller D.M., et al., A meta-analysis of methylprednisolone in recovery from multiple sclerosis exacerbations. Mult Scler, 2000. 6(4): p. 267 - 73.

61. Filippini G., et al., Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev, 2000(4): p. CD001331.

62. Freedman M.S., et al., Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci, 2013. 40(3): p. 307 - 23.

63. Hofer S. et al. Management of Acute Demyelinating Attacks in the Pediatric Population: A Swiss Consensus Statement//Clinical and translational neuroscience. - 2021. - Т. 5. - N. 2. - С. 17.

64. Repovic P. and F.D. Lublin, Treatment of multiple sclerosis exacerbations. Neurol Clin, 2011. 29(2): p. 389 - 400.

65. La Mantia L., et al., Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol, 1994. 34(4): p. 199 - 203.

66. Narula S., New Perspectives in Pediatric Neurology-Multiple Sclerosis. Curr Probl Pediatr Adolesc Health Care, 2016. 46(2): p. 62 - 9.

67. Narula S., S.E. Hopkins, and B. Banwell, Treatment of pediatric multiple sclerosis. Curr Treat Options Neurol, 2015. 17(3): p. 336.

68. Waldman A.T., et al., Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. J Child Neurol, 2011. 26(6): p. 675 - 82.

69. Burton J.M., et al., Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev, 2012. 12: p. CD006921.

70. Le Page E., et al., Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet, 2015. 386(9997): p. 974 - 81.

71. Pena J.A. and T.E. Lotze, Pediatric multiple sclerosis: current concepts and consensus definitions. Autoimmune Dis, 2013. 2013: p. 673947.

72. Ramo-Tello C., et al., A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler, 2014. 20(6): p. 717 - 25.

73. Liu S., et al., Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials. PLoS One, 2017. 12(11): p. e0188644.

74. Weiner H.L., et al., Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology, 1989. 39(9): p. 1143 - 9.

75. Weinshenker B.G., et al., A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol, 1999. 46(6): p. 878 - 86.

76. Cortese I., et al., Evidence-based guideline update: Plasmapheresis in neurologic disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2011. 76(3): p. 294 - 300.

77. Spalice A., et al., Intravenous immunoglobulin and interferon: successful treatment of optic neuritis in pediatric multiple sclerosis. J Child Neurol, 2004. 19(8): p. 623 - 6.

78. Apak R.A., B. Anlar, and I. Saatci, A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev, 1999. 21(4): p. 279 - 82.

79. Darabi K., O. Abdel-Wahab, and W.H. Dzik, Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion, 2006. 46(5): p. 741 - 53.

80. Trebst C. and M. Stangel, Promotion of remyelination by immunoglobulins: implications for the treatment of multiple sclerosis. Curr Pharm Des, 2006. 12(2): p. 241 - 9.

81. Nikfar S., R. Rahimi, and M. Abdollahi, A meta-analysis of the efficacy and tolerability of interferon- in multiple sclerosis, overall and by drug and disease type. Clin Ther, 2010. 32(11): p. 1871 - 88.

82. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet, 1998. 352(9139): p. 1498 - 504.

83. La Mantia L., et al., Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev, 2016. 11(11): p. CD009333.

84. Newsome S.D., et al., Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis. J Neurol, 2016. 263(9): p. 1778 - 87.

85. Kieseier B.C., et al., Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. Mult Scler, 2015. 21(8): p. 1025 - 35.

86. Tolley K., et al., A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis. PLoS One, 2015. 10(6): p. e0127960.

87. Comi G., M. Filippi, and J.S. Wolinsky, European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol, 2001. 49(3): p. 290 - 7.

88. Khan O., et al., Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol, 2013. 73(6): p. 705 - 13.

89. Gold R., et al., Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med, 2012. 367(12): p. 1098 - 107.

90. Xu Z., et al., Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev, 2015. 2015(4): p. CD011076.

91. Durelli L., et al., Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet, 2002. 359(9316): p. 1453 - 60.

92. Бойко А.Н., Бахтиярова К.З., Бойко О.В., Дудин В.А., Заславский Л.Г., Малкова Н.А., Паршина Е.В., Повереннова И.Е., Сиверцева С.А., Тотолян Н.А., Щур С.Г., Хабиров Ф.А., Гончарова З.А., Захарова М.Н., Болсун Д.Д., Зинкина-Орихан А.В., Линькова Ю.Н., Черновская Т.В., Порозова А.А. Долгосрочные данные по эффективности и безопасности препарата сампэгинтерферон- у пациентов с ремиттирующим рассеянным склерозом: результаты 104-недельного рандомизированного двойного слепого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова, 2023; 123(2): 52 - 59.

93. Бойко А.Н., Бойко О.В., Бахтиярова К.З., Гусев Е.И., Дудин В.А., Заславский Л.Г., Малкова Н.А., Паршина Е.В., Повереннова И.Е., Сиверцева С.А., Тотолян Н.А., Щур С.Г., Федулов А.С., Хабиров Ф.А., Болсун Д.Д., Зинкина-Орихан А.В., Линькова Ю.Н., Черновская Т.В. Эффективность и безопасность сампэгинтерферона для лечения ремиттирующего рассеянного склероза: результаты 52-недельного рандомизированного двойного слепого клинического исследования. Журнал неврологии и психиатрии им. С.С. Корсакова, 2022; 122(1): 62 - 71

94. Brown J.W.L., et al., Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA, 2019. 321(2): p. 175 - 187.

95. Ghezzi A., et al., Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci, 2009. 30(3): p. 193 - 9.

96. Baroncini D., et al., Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. Mult Scler, 2019. 25(3): p. 399 - 407.

97. Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, Goodkin D. Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics. 2001 Aug; 32(4): 211 - 3. doi: 10.1055/s-2001-17370

98. Tenembaum S.N., et al., Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol, 2013. 28(7): p. 849 - 56.

99. Costa G.D. and G. Comi, Teriflunomide: an oral therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis. Expert Rev Neurother, 2023. 23(8): p. 681 - 687.

100. Chitnis T., et al., Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol, 2021. 20(12): p. 1001 - 1011.

101. Nicotera A.G., et al., Treatment of multiple sclerosis in children: A brief overview. Clin Immunol, 2022. 237: p. 108947.

102. Ghezzi A. and I.T.o.E.O.M.I. Group, Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study. Neurol Sci, 2005. 26 Suppl 4: p. S183 - 6.

103. Ghezzi A., et al., Pediatric multiple sclerosis: Conventional first-line treatment and general management. Neurology, 2016. 87(9 Suppl 2): p. S97 - S102.

104. Jakimovski D., et al., Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs, 2022. 36(1): p. 45 - 59.

105. Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics. 2003 Jun; 34(3): 120 - 6. doi: 10.1055/s-2003-41274

106. Alroughani R., et al., Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Pediatr Neurol, 2018. 83: p. 19 - 24.

107. Parks N.E., et al., NEDA treatment target? No evident disease activity as an actionable outcome in practice. J Neurol Sci, 2017. 383: p. 31 - 34.

108. Rotstein D.L., et al., Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol, 2015. 72(2): p. 152 - 8.

109. Giovannoni G., et al., Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord, 2015. 4(4): p. 329 - 33.

110. Hohlfeld R. and E. Meinl, Ocrelizumab in multiple sclerosis: markers and mechanisms. Lancet Neurol, 2017. 16(4): p. 259 - 261.

111. Giovannoni G., Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics, 2017. 14(4): p. 874 - 887.

112. Hauser S.L., et al., Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med, 2020. 383(6): p. 546 - 557.

113. Bar-Or A., et al., Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler, 2022. 28(6): p. 910 - 924.

114. Davis M.D., et al., Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study. Neurol Neuroimmunol Neuroinflamm, 2017. 4(2): p. e327.

115. Kappos L., et al., Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet, 2018. 391(10127): p. 1263 - 1273.

116. Freedman M.S., et al., Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. Can J Neurol Sci, 2020. 47(4): p. 437 - 455.

117. Cohen J.A., et al., Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol, 2019. 18(11): p. 1021 - 1033.

118. Comi G., et al., Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol, 2019. 18(11): p. 1009 - 1020.

119. Giovannoni G., et al., A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med, 2010. 362(5): p. 416 - 26.

120. Rammohan K., et al., Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Mult Scler Relat Disord, 2012. 1(1): p. 49 - 54.

121. Zanetta C., et al., Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study. J Neurol, 2023. 270(7): p. 3553 - 3564.

122. Miravalle A.A., et al., CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis. Neurodegener Dis Manag, 2021. 11(2): p. 99 - 111.

123. Совет экспертов "Кладрибин в таблетках в реальной клинической практике" (01 июня 2022 г, Санкт-Петербург).-URL.: https://www.mapcms.ru/projects/events/sovet-ekspertov-kladribin-v-tabletkakh-v-realnoy-klinicheskoy-praktike/

124. Miravalle A, Katz J, Robertson D, Aldridge J, Evans E, Harlow DE Cladribine Tablets in Patients With Relapsing-Remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis After Suboptimal Response to a Disease-Modifying Therapy (CLICK-MS and MASTER-2): Interim Baseline and Safety Review (P1-1.Virtual). 2022; 98 (18_supplement) https://doi.org/10.1212/WNL.98.18_supplement.824

125. Hauser S.L., et al., Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Mult Scler, 2023. 29(11-12): p. 1452 - 1464.

126. Cohen J, Gold R, J. de , Robertson D, Wiendl H, Wray S, et al. Efficacy of Early Ofatumumab versus Late-Switch from Teriflunomide: Subgroup Analysis of the ALITHIOS Open-Label Extension Study by Prior Disease Modifying Therapy Exposure and Age. ECTRIMS 2022. LB Poster 1210. Multiple Sclerosis Journal. 2022; 28(3): 956 - 83. Doi:10.1177/13524585221126909

127. А.Н. Бойко, В.М. Алифирова, И.Г. Лукашевич, З.А. Гончарова, И.В. Грешнова, Л.Г. Заславский, С.В. Котов, Н.А. Малкова, Г.Н. Мишин, Е.В. Паршина, И.Е. Повереннова, Л.Н. Прахова, С.А. Сиверцева, И.В. Смагина, Н.А. Тотолян, Ю.В. Тринитатский, Т.Н. Трушникова, Ф.А. Хабиров, Ж.Ю. Чефранова, С.Г. Щур, В.А. Дудин, Д.В. Похабов, Д.Д. Болсун, А.В. Еремеева, Ю.Н. Линькова, А.В. Зинкина-Орихан. Эффективность и безопасность 48-недельного применения моноклонального антитела против CD20 дивозилимаба у пациентов с рассеянным склерозом: результаты рандомизированного двойного слепого плацебо-контролируемого клинического исследования BCD-132-4/MIRANTIBUS. Журнал неврологии и психиатрии им. С.С. Корсакова, 2023; Вып. 123(7 вып. 2): 1 - 10. https://doi.org/10.17116/jnevro20231230721

128. А.Н. Бойко, В.М. Алифирова, И.Г. Лукашевич, З.А. Гончарова, И.В. Грешнов, Л.Г. Заславский, С.В. Котов, Н.А. Малкова, Г.Н. Мишин, Е.В. Паршина, И.Е. Повереннова, Л.Н. Прахова, С.А. Сиверцева, И.В. Смагина, Н.А. Тотолян, Ю.В. Тринитатский, Т.Н. Трушникова, Ф.А. Хабиров, С.Г. Щур, А.В. Артемьева, Д.Д. Болсун, А.В. Зинкина-Орихан, Ю.Н. Линькова. Эффективность и безопасность 24 недель применения дивозилимаба среди пациентов с рассеянным склерозом в рамках рандомизированного двойного слепого плацебо-контролируемого клинического исследования BCD-132-2. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123(4): 1 - 11. https://doi.org/10.17116/jnevro20231230411

129. Polman C.H., et al., A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med, 2006. 354(9): p. 899 - 910.

130. Pucci E., et al., Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst Rev, 2011(10): p. CD007621.

131. Bomprezzi R. and S. Pawate, Extended interval dosing of natalizumab: a two-center, 7-year experience. Ther Adv Neurol Disord, 2014. 7(5): p. 227 - 31.

132. Clerico M., et al., Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? Neurotherapeutics, 2020. 17(1): p. 200 - 207.

133. Yamout B.I., et al., Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord, 2018. 24: p. 113 - 116.

134. Calabresi P.A., et al., Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol, 2014. 13(6): p. 545 - 56.

135. La Mantia L., et al., Fingolimod for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev, 2016. 4(4): p. CD009371.

136. Chitnis T., et al., Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. N Engl J Med, 2018. 379(11): p. 1017 - 1027.

137. Sun Y., et al., Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Pharmacol, 2020. 11: p. 589146.

138. Zeposia (International non-proprietary name: ozanimod). Assessment report of EMA 2021. Amsterdam 16 June 2015; EMA/CHMP/199869/2020 Rev 2 Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/documents/assessment-report/zeposia-epar-public-assessment-report_en.pdf

139. Coles A.J., et al., Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1829 - 39.

140. Cohen J.A., et al., Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet, 2012. 380(9856): p. 1819 - 28.

141. Zhang J., et al., Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst Rev, 2017. 11(11): p. CD010968.

142. Hauser S.L., et al., Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med, 2017. 376(3): p. 221 - 234.

143. Menge T., et al., Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis. Expert Rev Neurother, 2016. 16(10): p. 1131 - 9.

144. Vermersch P., et al., Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:. Curr Med Res Opin, 2021. 37(3): p. 459 - 464.

145. Boneschi M.F., et al., Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev, 2013(5): p. CD002127.

146. Kira J.I., et al., Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study. Mult Scler, 2022. 28(8): p. 1229 - 1238.

147. Ghezzi A., et al., Natalizumab in the pediatric MS population: results of the Italian registry. BMC Neurol, 2015. 15: p. 174.

148. Ghezzi A., et al., Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. Neurol Neuroimmunol Neuroinflamm, 2019. 6(5): p. e591.

149. Vitaliti G., et al., Natalizumab in multiple sclerosis: discontinuation, progressive multifocal leukoencephalopathy and possible use in children. Expert Rev Neurother, 2015. 15(11): p. 1321 - 41.

150. Benallegue N., et al., Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. JAMA Neurol, 2024.

151. Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2): 137. doi: 10.1007/s00415-024-12879-z. PMID: 39812825; PMCID: PMC11735518

152. Skataric M, Savelieva M, Pigeolet E, Leppert D. Ofatumumab Dose Selection in Pediatric Population with Relapsing Multiple Sclerosis. Abstracts for the Ninth American Conference on Pharmacometrics (ACoP9). J Pharmacokinet Pharmacodyn 45 (Suppl 1), 3 - 134 (2018). https://doi.org/10.1007/s10928-018-9606-9.

153. Кузьминых Е.Д., Лебедев В.М., Сенченко В.Е., Черепянский М.С., Гончар В.А., Коробко Д.С. Первый опыт применения офатумумаба для лечения педиатрического рассеянного склероза в реальной российской клинической практике. Серия случаев. Неврология, нейропсихиатрия, психосоматика. 2025; 17(1): 72 - 77. DOI: 10.14412/2074-2711-2025-1-72-77 https://nnp.ima-press.net/nnp/article/view/2438/1767

154. Ahrweiller K., et al., Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. Mult Scler, 2020. 26(8): p. 924 - 935.

155. Paz M.M., et al., Relapses and disability accumulation in progressive multiple sclerosis. Neurology, 2015. 84(1): p. 81 - 8.

156. Kappos L., et al., Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Neurology, 2015. 85(1): p. 29 - 39.

157. Jokubaitis V.G., et al., Fingolimod after natalizumab and the risk of short-term relapse. Neurology, 2014. 82(14): p. 1204 - 11.

158. Pfeuffer S., et al., Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. J Neurol, 2019. 266(1): p. 165 - 173.

159. Mihalova T, Vernon K, Sharaf N, Talbot P, Rog D. 195 MS disease modifying therapy (DMT) sequencing - tysabri to mavenclad de-escalation in JC-virus positive MS patients. J Neurol Neurosurg Psychiatry. 2019; 90(12): e49 - e50. doi: 10.1136/jnnp-2019-abn-2.166

160. Switching from natalizumab to anti-CD20 monoclonal antibodies. ECTRIMS Online Library. Levin S. Sep 11 2019; 279030. https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279030/seth.levin.switching.from.natalizumab.to.anti-cd20.monoclonal.antibodies.html. Accessed June 1, 2020.

161. Hodgkinson S; Sharma M, 2019, 'Temporal profile of lymphocytes following treatment with cladribine tablets in patients switching from lymphocyte depleting or sequestering disease modifying drugs (DMDs) (P4.2-034), Neurology, 92, http://dx.doi.org/10.1212/wnl.92.15_supplement.p4.2-034

162. Vollmer B., et al., The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci, 2018. 390: p. 89 - 93.

163. Alping P., et al., Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Ann Neurol, 2016. 79(6): p. 950 - 8.

164. Евдошенко Е.П., Неофидов Н.А., Бахтиярова К.З., Давыдовская М.В., Каирбекова Е.И., Колонтарева Ю.М., Малкова Н.А., Одинак М.М., Попова Е.В., Сазонов Д.В., Столяров И.Д., Смагина И.В., Федянин А.С., Хабиров Ф.А., Хайбуллин Т.И., Хачанова Н.В., Щукин И.А., Бойко А.Н. Эффективность и безопасность сипонимода у пациентов с вторично-прогрессирующим рассеянным склерозом в российской популяции. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски, 2019. - 119(10-2). - 110 - 119.

165. Tong J., et al., Efficacy and acceptability of the S1P receptor in the treatment of multiple sclerosis: a meta-analysis. Neurol Sci, 2021. 42(5): p. 1687 - 1695.

166. Comi G, Bermel, R, Bar-Or, A, McGinley M, Arnold D, Henry R, et al. A multicentre, open label, single-arm, phase 3b study (CONSONANCE) to assess the effectiveness and safety of ocrelizumab in patients with primary and secondary progressive multiple sclerosis: year 2 interim analysis. Presented at the European Committee for Treatment and Research in Multiple Sclerosis in Amsterdam, The Netherlands. October 26 - 28, 2022. ECTRIMS Poster #P699.

167. La Mantia L., et al., Interferon beta for secondary progressive multiple sclerosis. Cochrane Database Syst Rev, 2012. 1: p. CD005181.

168. Montalban X., et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med, 2017. 376(3): p. 209 - 220.

169. Yang T.T., et al., Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. J Neurol Sci, 2017. 380: p. 256 - 261.

170. Van Kerrebroeck, P.E., et al., Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn, 1998. 17(5): p. 499 - 512.

171. V., E. Chartier-Kastler, and J.N. Panicker, Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol, 2016. 13(5): p. 275 - 88.

172. M, S, A, A, R, M. Effects of Treating an Overactive Urinary Bladder in Patients with Multiple Sclerosis. Acta Med Acad. 2019 Dec; 48(3): 271 - 277. doi: 10.5644/ama2006-124.267.

173. Nicholas R.S., et al., Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev, 2009(1): p. CD004193.

174. Harvey M.A., K. Baker, and G.A. Wells, Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: a meta-analysis. Am J Obstet Gynecol, 2001. 185(1): p. 56 - 61.

175. Ethans K.D., et al., Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med, 2004. 27(3): p. 214 - 8.

176. Amend, B., et al., Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol, 2008. 53(5): p. 1021 - 8.

177. Valiquette G., J. Herbert, and P. Maede-D'Alisera, Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. Arch Neurol, 1996. 53(12): p. 1270 - 5.

178. Hilton P., K. Hertogs, and S.L. Stanton, The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry, 1983. 46(9): p. 854 - 5.

179. Bientinesi R, Gandi C, Bassi P. Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies. Int Neurourol J. 2020 Jun; 24(2): 118 - 126. doi: 10.5213/inj.2040028.014

180. Stankovich E.I.u., V.V. Borisov, and T.L. Demina, [Tamsulosin in the treatment of detrusor-sphincter dyssynergia of the urinary bladder in patients with multiple sclerosis]. Urologiia, 2004(4): p. 48 - 51.

181. Шварц П.Г., Попов С.В. Нейрогенная хроническая задержка мочи у больных рассеянным склерозом. Трудный пациент, 2018; 6 (Том 16): 61 - 64

182. Khalaf K.M., et al., The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. Neurourol Urodyn, 2016. 35(1): p. 48 - 54.

183. Mehnert U., et al., The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol, 2010. 184(3): p. 1011 - 6.

184. Gallien P., et al., Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry, 2005. 76(12): p. 1670 - 6.

185. Schurch B., et al., Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol, 2005. 174(1): p. 196 - 200.

186. Cruz F., et al., Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol, 2011. 60(4): p. 742 - 50.

187. Mangera A., et al., Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol, 2011. 60(4): p. 784 - 95.

188. Brar S.P., et al., Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehabil, 1991. 72(3): p. 186 - 9.

189. Feldman R.G., et al., Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study. Neurology, 1978. 28(11): p. 1094 - 8.

190. Hudgson P. and D. Weightman, Baclofen in the treatment of spasticity. Br Med J, 1971. 4(5778): p. 15 - 7.

191. Orsnes G.B., et al., Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand, 2000. 101(4): p. 244 - 8.

192. Sachais B.A., J.N. Logue, and M.S. Carey, Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol, 1977. 34(7): p. 422 - 8.

193. Sawa G.M. and D.W. Paty, The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci, 1979. 6(3): p. 351 - 4.

194. Otero-Romero S., et al., Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Mult Scler, 2016. 22(11): p. 1386 - 1396.

195. А. Светляк, А.А. Лапковский, М.П. Бондаренко Симптоматическая терапия рассеянного склероза//Проблемы здоровья и экологии. 2007. N 1. URL: https://cyberleninka.ru/article/n/simptomaticheskaya-terapiya-rasseyannogo-skleroza:

196. Mueller M.E., et al., Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil, 1997. 78(5): p. 521 - 4.

197. Dressler D., et al., Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol, 2017. 264(1): p. 112 - 120.

198. Hyman N., et al., Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry, 2000. 68(6): p. 707 - 12.

199. Gusev YI, Banach M, Simonow A, et al. Efficacy and safety of botulinum type a toxin in adductor spasticity due to multiple sclerosis. J Musculoskelet Pain. 2008; 16(3): 175 - 188. doi: 10.1080/10582450802161952

200. Gracies J.M., et al., Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension. Neurology, 2017. 89(22): p. 2245 - 2253.

201. Grazko M.A., K.B. Polo, and B. Jabbari, Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology, 1995. 45(4): p. 712 - 7.

202. Konstanzer A., et al. Local injection treatment with botulinum toxin A in severe arm and leg spasticity. Nervenarzt, 1993. 64(8): p. 517 - 23.

203. A.D., et al., Botulinum toxin A in the treatment of spasticity - An open label study. J Back Musculoskelet Rehabil, 2002. 16(2): p. 51 - 6.

204. Fu X., et al., A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis. Clin Rehabil, 2018. 32(6): p. 713 - 721.

205. Neuropathic pain in adults: pharmacological management in non-specialist settings. London: National Institute for Health and Care Excellence (NICE); 2020 Sep 22. (NICE Clinical Guidelines, No. 173.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK552848/

206. Sieminski M., J. Losy, and M. Partinen, Restless legs syndrome in multiple sclerosis. Sleep Med Rev, 2015. 22: p. 15 - 22.

207. Braley T.J. and R.D. Chervin, A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis. Ther Adv Neurol Disord, 2015. 8(6): p. 294 - 310.

208. Valet M., et al., Effects of Fampridine in People with Multiple Sclerosis: A Systematic Review and Meta-analysis. CNS Drugs, 2019. 33(11): p. 1087 - 1099.

209. Jensen H.B., et al., 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review. Ther Adv Neurol Disord, 2014. 7(2): p. 97 - 113.

210. Goodman A.D., et al., Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology, 2008. 71(15): p. 1134 - 41.

211. Goodman A.D., et al., Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet, 2009. 373(9665): p. 732 - 8.

212. Goodman A.D., et al., A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol, 2010. 68(4): p. 494 - 502.

213. Столяров И.Д., Петров А.М., Бойко А.Н. Эффективность и безопасность препарата Кинезиа (фампридин) в комплексной терапии рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020; 120(11): 45 - 52.

214. Khan F. and B. Amatya. Rehabilitation in Multiple Sclerosis: A Systematic Review of Systematic Reviews. Arch Phys Med Rehabil, 2017. 98(2): p. 353 - 367.

215. Khan F., et al. Multidisciplinary rehabilitation for adults with multiple sclerosis. Cochrane Database Syst Rev, 2007. 2007(2): p. CD006036.

216. Freeman J.A., et al. The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol, 1997. 42(2): p. 236 - 44.

217. Craig J., et al., A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment. J Neurol Neurosurg Psychiatry, 2003. 74(9): p. 1225 - 30.

218. Francabandera F.L., et al., Multiple sclerosis rehabilitation: inpatient vs. outpatient. Rehabil Nurs, 1988. 13(5): p. 251 - 3.

219. Asano M., R. Raszewski, and M. Finlayson, Rehabilitation interventions for the management of multiple sclerosis relapse: a short scoping review. Int J MS Care, 2014. 16(2): p. 99 - 104.

220. Liu C., E.D. Playford, and A.J. Thompson, Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? J Neurol, 2003. 250(10): p. 1214 - 8.

221. Baert I., et al., Responsiveness and clinically meaningful improvement, according to disability level, of five walking measures after rehabilitation in multiple sclerosis: a European multicenter study. Neurorehabil Neural Repair, 2014. 28(7): p. 621 - 31.

222. Baert I., et al., Responsiveness and meaningful improvement of mobility measures following MS rehabilitation. Neurology, 2018. 91(20): p. e1880 - e1892.

223. Sackett D.L., et al., Evidence based medicine: what it is and what it isn't. BMJ, 1996. 312(7023): p. 71 - 2.

224. Khan F., et al., Effectiveness of rehabilitation intervention in persons with multiple sclerosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry, 2008. 79(11): p. 1230 - 5.

225. Pozzilli C., et al., Home based management in multiple sclerosis: results of a randomised controlled trial. J Neurol Neurosurg Psychiatry, 2002. 73(3): p. 250 - 5.

226. Solari A., et al., Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology, 1999. 52(1): p. 57 - 62.

227. WHO | International Classification of Functioning, Disability and Health (ICF). WHO. 2019.

228. Holper L., et al., Characterization of functioning in multiple sclerosis using the ICF. J Neurol, 2010. 257(1): p. 103 - 13.

229. Coenen M., et al., The development of ICF Core Sets for multiple sclerosis: results of the International Consensus Conference. J Neurol, 2011. 258(8): p. 1477 - 88.

230. Conrad A., et al., Validation of the comprehensive ICF core set for multiple sclerosis from the perspective of physical therapists. Phys Ther, 2012. 92(6): p. 799 - 820.

231. Dalgas U., et al., Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology, 2009. 73(18): p. 1478 - 84.

232. White L.J. and V. Castellano, Exercise and brain health--implications for multiple sclerosis: Part 1--neuronal growth factors. Sports Med, 2008. 38(2): p. 91 - 100.

233. White L.J. and V. Castellano, Exercise and brain health--implications for multiple sclerosis: Part II--immune factors and stress hormones. Sports Med, 2008. 38(3): p. 179 - 86.

234. Gottschalk M., et al., Fatigue and regulation of the hypothalamo-pituitary-adrenal axis in multiple sclerosis. Arch Neurol, 2005. 62(2): p. 277 - 80.

235. Heine M., et al., Exercise therapy for fatigue in multiple sclerosis. Cochrane Database Syst Rev, 2015. 2015(9): p. CD009956.

236. Asano M. and M.L. Finlayson, Meta-analysis of three different types of fatigue management interventions for people with multiple sclerosis: exercise, education, and medication. Mult Scler Int, 2014. 2014: p. 798285.

237. Kargarfard M., et al., Randomized Controlled Trial to Examine the Impact of Aquatic Exercise Training on Functional Capacity, Balance, and Perceptions of Fatigue in Female Patients With Multiple Sclerosis. Arch Phys Med Rehabil, 2018. 99(2): p. 234 - 241.

238. Corvillo I., et al., Efficacy of aquatic therapy for multiple sclerosis: a systematic review. Eur J Phys Rehabil Med, 2017. 53(6): p. 944 - 952.

239. Velikonja O., et al., Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg, 2010. 112(7): p. 597 - 601.

240. Haselkorn J.K., et al., Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 2015. 85(21): p. 1896 - 903.

241. Steultjens E.M., et al., Occupational therapy for multiple sclerosis. Cochrane Database Syst Rev, 2003. 2003(3): p. CD003608.

242. Lamers I., et al., Upper Limb Rehabilitation in People With Multiple Sclerosis: A Systematic Review. Neurorehabil Neural Repair, 2016. 30(8): p. 773 - 93.

243. Martinez-Assucena A, Marnetoft S-U, Rovira TR, Hernandez-San-Miguel J, Bernabeu M, Martinell-Gispert-Sauch M. Rehabilitation for Multiple Sclerosis, in Adults (II); Management and Impact on Impairment, Functioning, and Quality of Life: An Overview. Crit Rev Phys Rehabil Med. 2010; 22(1-4): 179 - 139. doi: 10.1615/CritRevPhysRehabilMed.v22.i1-4.100

244. Portillo M.C., et al., Evaluation of a nurse-led social rehabilitation programme for neurological patients and carers: an action research study. Int J Nurs Stud, 2009. 46(2): p. 204 - 19.

245. Gunn H., et al., Systematic Review: The Effectiveness of Interventions to Reduce Falls and Improve Balance in Adults With Multiple Sclerosis. Arch Phys Med Rehabil, 2015. 96(10): p. 1898 - 912.

246. Ahmadi A., et al., Comparison of the Effect of 8 weeks Aerobic and Yoga Training on Ambulatory Function, Fatigue and Mood Status in MS Patients. Iran Red Crescent Med J, 2013. 15(6): p. 449 - 54.

247. Hebert J.R., et al., Efficacy of Balance and Eye-Movement Exercises for Persons With Multiple Sclerosis (BEEMS). Neurology, 2018. 90(9): p. e797 - e807.

248. Gandolfi M., et al., Sensory integration balance training in patients with multiple sclerosis: A randomized, controlled trial. Mult Scler, 2015. 21(11): p. 1453 - 62.

249. Brichetto G., et al., The effect of Nintendo(R) Wii(R) on balance in people with multiple sclerosis: a pilot randomized control study. Mult Scler, 2013. 19(9): p. 1219 - 21.

250. Casuso-Holgado, M.J., et al., Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis. Clin Rehabil, 2018. 32(9): p. 1220 - 1234.

251. Straudi S., et al., The effects of robot-assisted gait training in progressive multiple sclerosis: A randomized controlled trial. Mult Scler, 2016. 22(3): p. 373 - 84.

252. McGibbon C.A., et al., Evaluation of the Keeogo exoskeleton for assisting ambulatory activities in people with multiple sclerosis: an open-label, randomized, cross-over trial. J Neuroeng Rehabil, 2018. 15(1): p. 117.

253. Afzal T., et al., Exoskeleton-assisted Gait Training in Persons With Multiple Sclerosis: A Single-Group Pilot Study. Arch Phys Med Rehabil, 2020. 101(4): p. 599 - 606.

254. Miller L., et al., Functional Electrical Stimulation for Foot Drop in Multiple Sclerosis: A Systematic Review and Meta-Analysis of the Effect on Gait Speed. Arch Phys Med Rehabil, 2017. 98(7): p. 1435 - 1452.

255. Amatya B., et al., Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev, 2013(2): p. CD009974.

256. Splinting for the Prevention and Correction of Contractures in Adults with Neurological Dysfunction Association of Chartered Physiotherapists in Neurology. www.COT.org.uk. Accessed April 15, 2020.

257. Harvey L, de Jong I, Goehl G, Mardwedel S. Twelve weeks of nightly stretch does not reduce thumb web-space contractures in people with a neurological condition: a randomised controlled trial. Aust J Physiother. 2006; 52(4): 251 - 258. doi: 10.1016/s0004-9514(06)70004-6

258. Lannin N.A., et al., Effects of splinting on wrist contracture after stroke: a randomized controlled trial. Stroke, 2007. 38(1): p. 111 - 6.

259. Kinnear B.Z., et al., Rehabilitation therapies after botulinum toxin-A injection to manage limb spasticity: a systematic review. Phys Ther, 2014. 94(11): p. 1569 - 81.

260. E.M. and P.I. , Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev, 2011(11): p. CD009131.

261. E.M. and P.I. , Neuropsychological rehabilitation for multiple sclerosis. Cochrane Database Syst Rev, 2014(2): p. CD009131.

262. das Nair R., et al., Memory Rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev, 2012(3): p. CD008754.

263. Bombardier C.H., et al., Telephone-based physical activity counseling for major depression in people with multiple sclerosis. J Consult Clin Psychol, 2013. 81(1): p. 89 - 99.

264. Forman A.C. and N.B. Lincoln, Evaluation of an adjustment group for people with multiple sclerosis: a pilot randomized controlled trial. Clin Rehabil, 2010. 24(3): p. 211 - 21.

265. Group G.C., The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler, 2005. 11(3): p. 328 - 37.

266. Patti F., et al., The impact of outpatient rehabilitation on quality of life in multiple sclerosis. J Neurol, 2002. 249(8): p. 1027 - 33.

267. Patti F., et al., Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients--a randomised controlled trial. J Neurol, 2003. 250(7): p. 861 - 6.

268. Fiest K.M., et al., Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord, 2016. 5: p. 12 - 26.

269. Khan F., et al., Telerehabilitation for persons with multiple sclerosis. Cochrane Database Syst Rev, 2015. 2015(4): p. CD010508.

270. Block V., et al., Do Physical Therapy Interventions Affect Urinary Incontinence and Quality of Life in People with Multiple Sclerosis?: An Evidence-Based Review. Int J MS Care, 2015. 17(4): p. 172 - 80.

271. Mahler M.E., Behavioral manifestations associated with multiple sclerosis. Psychiatr Clin North Am, 1992. 15(2): p. 427 - 38.

272. Rodriguez M., et al., Impairment, disability, and handicap in multiple sclerosis: a population-based study in Olmsted County, Minnesota. Neurology, 1994. 44(1): p. 28 - 33.

273. Otero-Romero S, C, Reyes S, Amato MP, Campins M, Farez M, Filippi M, Hacohen Y, Hemmer B, Juuti R, Magyari M, Oreja-Guevara C, Siva A, Vukusic S, M. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023 Jul; 29(8): 904 - 925

274. Sorensen S.P., et al., The Multiple Sclerosis Care Unit. Mult Scler, 2019. 25(5): p. 627 - 636.

275. Avasarala J.R., et al., Analysis of NAMCS data for multiple sclerosis, 1998 - 2004. BMC Med, 2007. 5: p. 6.

276. S., et al., Real-World Treatment of Patients with Multiple Sclerosis per MS Subtype and Associated Healthcare Resource Use: An Analysis Based on 13,333 Patients in Germany. Neurol Ther, 2020. 9(1): p. 67 - 83.

277. Спирин Н., Бойко А., Степанов И., Шмитд Д. Ведение Пациентов Рассеянным Склерозом. Методические Рекомендации. Москва: РООИ "Здоровье человека"; 2015.

278. Kaplan T.B., Management of Demyelinating Disorders in Pregnancy. Neurol Clin, 2019. 37(1): p. 17 - 30.

279. Попова Е., Кукель Т., Муравин А. Ретроспективный анализ течения беременности и родов у женщин с рассеянным склерозом. Журнал неврологии и психиатрии им С.С. Корсакова. - 2013. - 2(10). - 52 - 56.

280. Попова Е., Коробко Д., Булатова Е. Ретроспективный анализ влияния беременности на течение рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. - 2015. - 2(8). - 18 - 21.

281. Confavreux C., et al., Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med, 1998. 339(5): p. 285 - 91.

282. Filippi M., et al., MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol, 2016. 15(3): p. 292 - 303.

283. Dickerson E., et al., Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. J Am Coll Radiol, 2017. 14(3): p. 371 - 379.e1.

284. Alrouji M., et al., Effects of cigarette smoke on immunity, neuroinflammation and multiple sclerosis. J Neuroimmunol, 2019. 329: p. 24 - 34.

285. Wingerchuk D.M., Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord, 2012. 5(1): p. 13 - 22.

286. Pierrot-Deseilligny C. and J.C. Souberbielle, Vitamin D and multiple sclerosis: An update. Mult Scler Relat Disord, 2017. 14: p. 35 - 45.

287. Pierrot-Deseilligny C., et al., Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord, 2012. 5(4): p. 187 - 98.

288. Laursen J.H., et al., Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Mult Scler Relat Disord, 2016. 10: p. 169 - 173.

289. Sollini ML, Pellegrino C, Barone G, Capitanucci ML, Zaccara AM, Crescentini L, Castelli E, Della Bella G, Scorletti F, Papetti L, Monte G, Ferilli MAN, Valeriani M, Mosiello G. Lower Urinary Tract Dysfunction in Pediatric Patients with Multiple Sclerosis: Diagnostic and Management Concerns. Children (Basel). 2024 May 16; 11(5): 601. doi: 10.3390/children11050601.

290. Bientinesi R, Gavi F, Coluzzi S, Nociti V, Marturano M, Sacco E. Neurologic Urinary Incontinence, Lower Urinary Tract Symptoms and Sexual Dysfunctions in Multiple Sclerosis: Expert Opinions Based on the Review of Current Evidences. J Clin Med. 2022 Nov 5; 11(21): 6572. doi: 10.3390/jcm11216572.

291. Rommer P.S., et al., Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol, 2014. 175(3): p. 397 - 407.

292. Wroe S.J., Effects of dose titration on tolerability and efficacy of interferon beta-1b in people with multiple sclerosis. J Int Med Res, 2005. 33(3): p. 309 - 18.

293. Ghezzi A., Therapeutic strategies in childhood multiple sclerosis. Ther Adv Neurol Disord, 2010. 3(4): p. 217 - 28.

294. Касаткин Д., Спирин Н., Бойко А., Власов Я. Унификация оценки побочных эффектов терапии препаратами, изменяющими течение рассеянного склероза. Журнал неврологии и психиатрии им С.С. Корсакова. - 2014. - (2). 78 - 82.

295. Wiendl H, Gold R, Berger T, et al. "Multiple Sclerosis Therapy Consensus Group" (MSTCG). Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Ther Adv Neurol Disord. 2021 Aug 18; 14: 17562864211039648. doi: 10.1177/17562864211039648.

296. Хачанова Н.В., Горохова Т.В. Расширение возможностей терапии рассеянного склероза новым препаратом для приема внутрь - терифлуномидом (абаджио). Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 2(2): 61 - 65

297. Winkelmann A., et al., Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol, 2016. 12(4): p. 217 - 33.

298. Havla J., et al., Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis. Dtsch Arztebl Int, 2016. 113(51-52): p. 879 - 886.

299. Бойко А.Н. Давыдовская М.В., Хачанова Н.В., Захарова М.Н., Спирин Н.Н., Попова Е.В., Алифирова В.М., Власов Я.В., Сиверцева С.А., Хабиров Ф.А., Шумилина М.В., Евдошенко Е.П. Клинические рекомендации по применению препарата окрелизумаб у пациентов с рассеянным склерозом. Неврология, нейропсихиатрия, психосоматика. 2019; 11(3): 16 - 25. https://doi.org/10.14412/2074-2711-2019-3-16-25

300. Barclay K, Carruthers R, Traboulsee A, Bass AD, LaGanke C, Bertolotto A, Boster A, Celius EG, de Seze J, Cruz DD, Habek M, Lee JM, Limmroth V, Meuth SG, Oreja-Guevara C, Pagnotta P, Vos C, Ziemssen T, Baker DP, Wijmeersch BV. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Front Neurol. 2019 Mar 22; 10: 253. doi: 10.3389/fneur.2019.00253.

301. Бахтиярова К.З., Бойко А.Н., Власов Я.В. и др. Рекомендации по использованию кладрибина в таблетках для патогенетического лечения пациентов с высокоактивным рассеянным склерозом. Неврология, нейропсихиатрия, психосоматика. 2020; 12(3): 93 - 99. DOI: 10.14412/2074-2711-2020-3-93-99

302. EMA 2019. Mayzent. Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/mayzent-epar-product-information_en.pdf

303. Rubin M., & Kutz, C. (2024). Ozanimod: A Practical Review for Nurses and Advanced Practice Providers. Nursing: Research and Reviews, 14, 15 - 31. https://doi.org/10.2147/NRR.S427698

304. Dumitrescu L, Papathanasiou A, Coclitu C, Garjani A, Evangelou N, Constantinescu CS, Popescu BO, Tanasescu R. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis. Expert Opin Pharmacother. 2023 Mar; 24(4): 495 - 509. doi: 10.1080/14656566.2023.2178898.

305. Coyle PK, Freedman MS, Cohen BA, Cree BAC, Markowitz CE. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review. Ann Clin Transl Neurol. 2024 Apr; 11(4): 842 - 855. doi: 10.1002/acn3.52017

306. Huth F., et al., Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug-Drug Interaction Potential of Siponimod With Physiologically-Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations. Clin Pharmacol Ther, 2019. 106(5): p. 1113 - 1124.

307. Алифирова В.М., Бойко А.Н., Власов Я.В., и др. Клинические рекомендации по применению препарата диметилфумарат при ремиттирующе-рецидивирующем рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2017; 117(1): 97 - 102

308. Linker R.A. and G. Wendt, Cardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study. Neurol Ther, 2016. 5(2): p. 193 - 201.

309. Singer BA. Initiating oral fingolimod treatment in patients with multiple sclerosis. Ther Adv Neurol Disord. 2013 Jul; 6(4): 269 - 75. doi: 10.1177/1756285613491520.

310. Piri Cinar B, Konuskan B, Anlar B, Ozakbas S. Narrative review based on fingolimod therapy in pediatric MS. SAGE Open Med. 2023 May 8; 11: 20503121231171996. doi: 10.1177/20503121231171996.

311. Petruzzo M, Lanzillo R. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report. Neurol Sci. 2021 May; 42 (Suppl 1): 37 - 39. doi: 10.1007/s10072-021-05086-5.

312. Sabsabi S, Mikhael E, Jalkh G, Macaron G, Rensel M. Clinical Evaluation of Siponimod for the Treatment of Secondary Progressive Multiple Sclerosis: Pathophysiology, Efficacy, Safety, Patient Acceptability and Adherence. Patient Prefer Adherence. 2022 May 24; 16: 1307 - 1319. doi: 10.2147/PPA.S221882.

313. Scott L.J., Siponimod: A Review in Secondary Progressive Multiple Sclerosis. CNS Drugs, 2020. 34(11): p. 1191 - 1200.

314. Mayzent (International non-proprietary name: siponimod). Assessment report of EMA 2019. EMA/CHMP/652767/2019. Rev 2 Committee for Medicinal Products for Human Use (CHMP). https://www.ema.europa.eu/en/documents/assessment-report/mayzent-epar-public-assessment-report_en.pdf

315. EMA 2020. Zeposia. Summary of product characteristics. https://ec.europa.eu/health/documents/community register/2021/20211118153769/anx_153769_en.pdf

316. Tugemann B, Berger JR. Improving risk-stratification of natalizumab-associated PML. Ann Clin Transl Neurol. 2021 Mar; 8(3): 696 - 703. doi: 10.1002/acn3.51130.

317. Williamson E.M.L. and J.R. Berger, Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. Neurotherapeutics, 2017. 14(4): p. 961 - 973.

318. Polman C.H., et al., Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol, 2010. 9(7): p. 740 - 50.

319. Goodin D.S., et al., Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2007. 68(13): p. 977 - 84.

320. Rudick R.A. and C.H. Polman, Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol, 2009. 8(6): p. 545 - 59.

321. Sorensen P.S., et al., Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology, 2005. 65(1): p. 33 - 9.

322. Kappos L., et al., Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology, 2005. 65(1): p. 40 - 7.

323. van der Voort L.F., et al., Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol, 2010. 67(4): p. 402 - 7.

324. Malucchi S., et al., One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. J Neurol, 2011. 258(5): p. 895 - 903.

325. Алифирова В.М. Клинические рекомендации по применению препарата алемтузумаб (Лемтрада)/Алифирова В.М., Бисага Г.Н., Бойко А.Н., Брюхов В.В., Давыдовская М.В., Захарова М.Н., Захарова Е.В., Малкова Н.А., Попова Е.В., Салогуб Г.Н., Сиверцева С.А., Трошина Е.А., Хачанова Н.В., Шмидт Т.Е.//Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. - 2017. - 117(2-2). - 115 - 126

326. Хачанова Н.В. Обновленные рекомендации совета экспертов по применению и обеспечению безопасности терапии препаратом алемтузумаб (Лемтрада)/Хачанова Н.В., Бахтиярова К.З., Бойко А.Н., Власов Я.В., Давыдовская М.В., Евдошенко Е.П., Захарова М.Н., Котов С.В., Попова Е.В., Сиверцева С.А., Тотолян Н.А., Хабиров Ф.А.//Ж. Неврологии и психиатрии им. Корсакова. - 2020. - N 120 (3). - С. 77 - 86

327. Касаткин Д.С., Коробко Д.С., Матсон М.Д., Лендоева Д.В., Иванова С.П. Вакцинопрофилактика при рассеянном склерозе. Журнал неврологии и психиатрии им. С.С. Корсакова. 2022; 122(9): 29 - 36.

328. Chataway J., et al., Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial. Lancet Neurol, 2006. 5(7): p. 565 - 71.

329. Hobart J., et al., International consensus on quality standards for brain health-focused care in multiple sclerosis. Mult Scler, 2019. 25(13): p. 1809 - 1818.

330. Lunny C., J.A. Knopp-Sihota, and S.N. Fraser, Surgery and risk for multiple sclerosis: a systematic review and meta-analysis of case-control studies. BMC Neurol, 2013. 13: p. 41.

331. De Lott L.B., et al., Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia. Mult Scler, 2020. 26(11): p. 1437 - 1440.

332. J. and P.H. Rosenberg, Anaesthesia for patients with multiple sclerosis. Ann Chir Gynaecol, 1984. 73(5): p. 299 - 303.

333. Dubuisson N, de Maere d'Aertrijcke O, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G, Verma V, Docquier MA. Anaesthetic management of people with multiple sclerosis. Mult Scler Relat Disord. 2023 Dec; 80: 105045. doi: 10.1016/j.msard.2023.105045.

334. Xiang X.M. and J. Bernard, Telehealth in Multiple Sclerosis Clinical Care and Research. Curr Neurol Neurosci Rep, 2021. 21(4): p. 14.

335. Polman C.H., et al., Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol, 2011. 69(2): p. 292 - 302.

336. EJ, Buckle GJ, Singer B, Singh V, Boster A. Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. Neurol Clin Pract. 2019 Feb; 9(1): 53 - 63. doi: 10.1212/CPJ.0000000000000567.

337. Walther, E.U., & Hohlfeld, R. (1999). Multiple sclerosis: Side effects of interferon beta therapy and their management. Neurology, 53(8), 1622 - 1622. doi: 10.1212/wnl.53.8.1622

338. Fischer S, Proschmann U, K, Ziemssen T. Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. Cells. 2021 Nov 15; 10(11): 3177. doi: 10.3390/cells10113177.

339. Wingerchuk D.M., et al., International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology, 2015. 85(2): p. 177 - 89.

340. Шток В., Левин О. Справочник По Формулированию Клинического Диагноза Болезней Нервной Системы. Москва; 2006.

341. Hyun J.W., et al., Utility of the rio score and modified rio score in korean patients with multiple sclerosis. PLoS One, 2015. 10(5): p. e0129243.

342. J., et al., Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler, 2008. 14(4): p. 479 - 84.

343. Sormani M.P., et al., Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler, 2013. 19(5): p. 605 - 12.

344. J., et al., Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. Mult Scler, 2014. 20(12): p. 1602 - 8.

345. J., et al., Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler, 2009. 15(7): p. 848 - 53.

346. Trojano M., et al., Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nat Rev Neurol, 2017. 13(2): p. 105 - 118.

347. Spelman T., et al., Comparative efficacy of switching to natalizumab in active multiple sclerosis. Ann Clin Transl Neurol, 2015. 2(4): p. 373 - 87.

348. Spelman T., et al., Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Eur J Neurol, 2016. 23(4): p. 729 - 36.

349. He A., et al., Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol, 2015. 72(4): p. 405 - 13.

350. Bateni H, Carruthers J, Mohan R. Pishva S. Use of Virtual Reality in Physical Therapy as an Intervention and Diagnostic Tool. Rehabil Res Pract. 2024 Jan 25; 2024: 1122286.

351. Alba-Rueda A, Lucena-Anton D, De Miguel-Rubio A. Effectiveness of two different exergaming systems ni addition ot conventional treatment for physical therapyin patients with multiple sclerosis: A study protocol for amulticenter, assessor-blind, 24-week, randomized controlled trial. Digit Health. 2024 Oct 18; 10: 20552076241287874.

352. Alba-Rueda A, De Miguel-Rubio A, Lucena-Anton D. Effectiveness of Nintendo Wit Physical Therapyin Patients with MultipleSclerosis: ASystematic Review and Meta-Analysis of Randomized Controlled Trials. Pers Med. 2024 Aug 24;14(9): 896.

353. Kubsik A, Klimkiewicz R, Janczewska K, Klimkiewicz P, Jankowska A, M. Application of laser radiation and magnetostimulation in therapy of patients with multiple sclerosis. NeuroRehabilitation. 2016; 38(2): 183 - 90.